Why Has Lake Street Given Heron Therapeutics (NASDAQ:HRTX) a $45.0 Price Target
Lake Street analyst started coverage on Heron Therapeutics (NASDAQ:HRTX) with a $45.0 PT and “Buy” rating. The PT provides a potential upside of 71.95% from company’s last stock close.
From a total of 7 analysts covering Heron Therapeutics (NASDAQ:HRTX) stock, 7 rate it a ”Buy”, 0 a “Sell”, and 0 a ”Hold”. This means that 100% of the ratings are positive. The highest target price is $56 while the lowest target price is $47. The mean of all analyst targets is $52.86 with a 103.17% above today’s ($26.17) stock price. Heron Therapeutics was the topic of 9 analyst reports since August 3, 2015 according to the firm StockzIntelligence Inc. Leerink Swann maintained shares on September 23 with “Outperform” rating. Bank of America initiated HRTX stock in a recent report from September 2 with “Buy” rating.
The stock closed the day at $26.17 during the previous session. It is down 120.84% since May 7, 2015 and is uptrending. It has outperformed by 122.78% the S&P500.
Heron Therapeutics, Inc. is a biotechnology company. The company has a market cap of $941.36 million. The Firm uses its technology to develop products to address unmet medical needs. It currently has negative earnings. The Company’s Biochronomer polymer drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals.
According to Zacks Investment Research, “Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting. Heron Therapeutics Inc., formerly known as A.P. Pharma, Inc., is based in REDWOOD CITY CA.” Get a free copy of the Zacks research report on Heron Therapeutics Inc (HRTX).